Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7277MR)

This product GTTS-WQ7277MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Age-related macular degeneration (AMD), Diabetic macular edema research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ7277MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8321MR IVTScrip™ mRNA-Anti-TFRC, HN-66000(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA HN-66000
GTTS-WQ8783MR IVTScrip™ mRNA-Anti-PCSK9, IBI-306(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA IBI-306
GTTS-WQ5236MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CB 2679d
GTTS-WQ5513MR IVTScrip™ mRNA-Anti-IL17A&IL17F, CDP4940(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CDP4940
GTTS-WQ11374MR IVTScrip™ mRNA-Anti-IGF, MEDI-573(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEDI-573
GTTS-WQ7637MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN1029(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA GEN1029
GTTS-WQ14233MR IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA RG-6107
GTTS-WQ5351MR IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CD38-Attenukine
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW